Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer (Q37249348)

19 August 2017

Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer (English)

1 reference

19 August 2017

0 references

1 reference

Alan Pollack

1

1 reference

19 August 2017

Gail Walker

2

1 reference

19 August 2017

Eric M Horwitz

3

1 reference

19 August 2017

Robert Price

4

1 reference

19 August 2017

Steven Feigenberg

5

1 reference

19 August 2017

Andre A Konski

6

1 reference

19 August 2017

Radka Stoyanova

7

1 reference

19 August 2017

Benjamin Movsas

8

1 reference

19 August 2017

Richard E Greenberg

9

1 reference

19 August 2017

Robert G Uzzo

10

1 reference

19 August 2017

Charlie Ma

11

1 reference

19 August 2017

Mark K Buyyounouski

12

1 reference

19 August 2017

language of work or name

English

0 references

publication date

7 October 2013

1 reference

Journal of Clinical Oncology

19 August 2017

1 reference

19 August 2017

31

1 reference

19 August 2017

31

1 reference

19 August 2017

3860-3868

1 reference

Estimation of α/β for late rectal toxicity based on RTOG 94-06

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

What dose of external-beam radiation is high enough for prostate cancer?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

The Gleason score shift: score four and seven years ago.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

Evaluation of survival data and two new rank order statistics arising in its consideration

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3805927

Cell kinetic measurements in prostate cancer

3 September 2018

1 reference

12 December 2020

Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel

1 reference

12 December 2020

What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy

1 reference

12 December 2020

Fractionation and late rectal toxicity

1 reference

12 December 2020

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

12 December 2020

External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS)

1 reference

12 December 2020

Updated Results and Patterns of Failure in a Randomized Hypofractionation Trial for High-risk Prostate Cancer

1 reference

12 December 2020

Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy

1 reference

12 December 2020

Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study

1 reference

12 December 2020

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2013.51.1972

1 reference

19 August 2017

1 reference

19 August 2017

1 reference